Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

639
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
639
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.

Annals of hematology·2026
Same author

Fludarabine-Treosulfan (FT10) Conditioning in Older AML Patients Undergoing Haploidentical Transplantation: A Prospective Italian Study With External Comparison to the Haplo-UK Reduced-Intensity Conditioning Cohort.

Transplantation and cellular therapy·2026
Same author

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026
Same author

Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.

Bone marrow transplantation·2026
Same author

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Leukemia·2026
Same author

Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.

Genes·2026

Related Experiment Video

Updated: Nov 20, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

451

Novel developments in chronic myeloid leukaemia.

Patrick Harrington1,2, Hugues de Lavallade1,2,3

  • 1School of Cancer & Pharmaceutical Science, King's College London.

Current Opinion in Hematology
|January 19, 2021
PubMed
Summary

Recent advances in chronic myeloid leukemia (CML) include new biomarkers for treatment-free remission and strategies for managing tyrosine kinase inhibitor (TKI) resistance. This review covers key clinical and pathophysiological developments in CML management.

More Related Videos

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

3.1K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.5K

Related Experiment Videos

Last Updated: Nov 20, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

451
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

3.1K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.5K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myeloid leukemia (CML) remains a significant hematologic malignancy.
  • Continuous research is vital for improving patient outcomes and understanding disease mechanisms.

Purpose of the Study:

  • To review significant advancements in chronic myeloid leukemia (CML) over the past year.
  • To highlight key developments in clinical management and disease pathophysiology.
  • To provide context with relevant prior publications.

Main Methods:

  • Conducted a PubMed search for relevant papers and abstracts from the last year.
  • Included pertinent earlier publications for comprehensive context.
  • Focused on clinical management, pathophysiology, and emerging therapeutic strategies.

Main Results:

  • Discussed novel biomarkers for achieving treatment-free remission in CML patients.
  • Reviewed outcomes from second-generation tyrosine kinase inhibitor (TKI) discontinuation studies.
  • Examined new techniques for assessing TKI resistance and novel management approaches for resistant cases, including combination therapies.

Conclusions:

  • The review summarizes critical research in CML, covering diagnostic techniques, biomarkers, and novel therapeutic options.
  • Emerging strategies offer new hope for managing CML, particularly in cases of resistance.
  • Continued investigation into CML pathophysiology and treatment is essential.